Nuveen LLC Acquires Shares of 226,202 Tenaya Therapeutics, Inc. $TNYA

Key Points

• Nuveen LLC has acquired approximately 226,202 shares of Tenaya Therapeutics, Inc., valued at around $129,000, increasing its ownership stake to about 0.26% as per the latest SEC filing.
• Multiple institutional investors have shown increased interest in Tenaya Therapeutics, with firms like Deutsche Bank AG boosting their holdings by over 300% during the fourth quarter.
• Analysts are generally optimistic about Tenaya Therapeutics, with a consensus rating of "Buy" and a price target averaging around $6.25.

Nuveen LLC acquired a new position in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 226,202 shares of the company's stock, valued at approximately $129,000. Nuveen LLC owned about 0.26% of Tenaya Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of TNYA. Woodline Partners LP bought a new stake in shares of Tenaya Therapeutics during the 4th quarter worth $28,000. Wealth Enhancement Advisory Services LLC bought a new position in Tenaya Therapeutics in the first quarter valued at about $33,000. CWM LLC raised its position in Tenaya Therapeutics by 14,231.7% in the first quarter. CWM LLC now owns 71,945 shares of the company's stock valued at $41,000 after purchasing an additional 71,443 shares during the last quarter. Hsbc Holdings PLC bought a new position in Tenaya Therapeutics in the fourth quarter valued at about $45,000. Finally, Virtu Financial LLC raised its position in Tenaya Therapeutics by 29.4% in the first quarter. Virtu Financial LLC now owns 135,502 shares of the company's stock valued at $77,000 after purchasing an additional 30,790 shares during the last quarter. 90.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

TNYA has been the subject of several research reports. HC Wainwright reiterated a "buy" rating and issued a $5.00 target price on shares of Tenaya Therapeutics in a research report on Tuesday, September 2nd. Chardan Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Tenaya Therapeutics in a research report on Thursday, August 7th. Finally, Wall Street Zen upgraded Tenaya Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $6.25.

Tenaya Therapeutics Stock Performance

Shares of TNYA traded down $0.08 during mid-day trading on Friday, reaching $1.20. 3,474,421 shares of the company were exchanged, compared to its average volume of 4,489,662. The stock has a market capitalization of $195.58 million, a PE ratio of -1.25 and a beta of 3.07. The business has a 50 day simple moving average of $0.93 and a two-hundred day simple moving average of $0.68. Tenaya Therapeutics, Inc. has a 52 week low of $0.36 and a 52 week high of $4.01.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.06. On average, analysts predict that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current year.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.